Published Technical Disclosure Archive

Synergistic Gene Therapy System for Mucopolysaccharidosis Type I

Publication ID: 24-11857641_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Gene Therapy System for Mucopolysaccharidosis Type I,” Published Technical Disclosure No. 24-11857641_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857641_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,641.

Summary of the Inventive Concept

A novel system integrating blockchain, AI, IoT, and gene therapy to provide personalized treatment for mucopolysaccharidosis type I, enhancing efficacy and reducing treatment costs.

Background and Problem Solved

Mucopolysaccharidosis type I (MPS I) is a debilitating genetic disorder with limited treatment options. The original patent disclosed a method for treating MPS I using gene therapy, but it has limitations in terms of treatment efficacy, patient monitoring, and data management. The present inventive concept addresses these limitations by combining gene therapy with blockchain, AI, and IoT technologies to create a more effective, efficient, and personalized treatment system.

Detailed Description of the Inventive Concept

The synergistic gene therapy system consists of several components: (1) a blockchain-based decentralized database for tracking patient treatment outcomes, ensuring data integrity and security; (2) a machine learning algorithm for predicting optimal gene therapy regimens based on patient-specific characteristics; (3) IoT-enabled sensors for real-time monitoring of treatment efficacy; (4) AI-designed gene therapy vectors with site-specific integration into the albumin locus; and (5) a system for optimizing gene therapy regimens using data from multiple sources. This integrated system enables personalized treatment, improves treatment outcomes, and reduces costs.

Novelty and Inventive Step

The new claims introduce the novel combination of blockchain, AI, IoT, and gene therapy, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more effective and efficient treatment system for MPS I.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different blockchain platforms, AI algorithms, or IoT sensors. Additionally, the system could be adapted for treating other genetic disorders or expanded to include additional features, such as telemedicine integration or patient engagement platforms.

Potential Commercial Applications and Market

The synergistic gene therapy system has significant commercial potential in the biotechnology and pharmaceutical industries, with a target market of patients with MPS I and other genetic disorders. The system's ability to provide personalized treatment, improve treatment outcomes, and reduce costs makes it an attractive solution for healthcare providers and payers.

CPC Classifications

SectionClassGroup
A A61 A61K48/005
A A61 A61K38/47
A A61 A61P3/00
C C12 C12Q1/34
C C12 C12Y301/06013
C C12 C12Y302/01076
G G01 G01N33/66

Field of Art

Gene therapy for lysosomal storage disorders, specifically mucopolysaccharidosis type I (MPS I), involving molecular biology, genetic engineering, vector design, and personalized medicine technologies

Person of Ordinary Skill (PHOSITA) Profile

A molecular biologist or genetic engineer with expertise in AAV vector design, gene therapy techniques, bioinformatics, and advanced computational methods for personalized medical interventions, holding a PhD or equivalent advanced degree with 3-5 years of specialized research experience

Obviousness Rationale

A PHOSITA would recognize that integrating computational technologies like AI, blockchain, and IoT with existing gene therapy approaches for MPS I represents a predictable extension of known personalized medicine strategies. The core gene therapy methodology remains consistent with the source patent, while the added technological layers provide enhanced monitoring and optimization capabilities. These technological integrations would be considered routine application of known computational techniques to an established medical treatment protocol.

Obvious Combinations & Variations

Source Patent Element
AAV vector-based gene therapy for MPS I treatment
PTD Variation
AI-designed gene therapy vectors with site-specific albumin locus integration
Obviousness Reasoning
Zinc finger nuclease technology for site-specific genomic integration is a known technique in gene therapy, and applying machine learning to vector design represents a predictable optimization of existing genetic engineering approaches
Source Patent Element
Treatment outcome tracking for MPS I patients
PTD Variation
Blockchain-based decentralized database for tracking patient treatment outcomes
Obviousness Reasoning
Secure, distributed data management is a standard approach in medical informatics, and applying blockchain to medical data tracking would be considered an obvious technological improvement by a PHOSITA
Source Patent Element
Gene therapy for genetic disorders
PTD Variation
Machine learning algorithms for predicting optimal gene therapy regimens
Obviousness Reasoning
Computational prediction of medical interventions using patient-specific data is a well-established technique in personalized medicine, representing a straightforward application of known computational methods to existing treatment protocols
Source Patent Element
MPS I treatment monitoring
PTD Variation
IoT-enabled sensors for real-time monitoring of treatment efficacy
Obviousness Reasoning
Remote patient monitoring using sensor technologies is a known approach in medical treatment, and applying such technologies to gene therapy represents a predictable extension of existing medical tracking methodologies
Source Patent Element
Gene therapy vector administration
PTD Variation
Integrated system for optimizing gene therapy regimens using multiple data sources
Obviousness Reasoning
Comprehensive data integration for treatment optimization is a standard approach in precision medicine, and would be considered an obvious refinement of existing treatment methodologies by a PHOSITA
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857641 and the present published technical disclosure, a person having ordinary skill in the art would find the claimed variations in gene therapy technologies for mucopolysaccharidosis type I treatment to be obvious and predictable extensions of the prior art. The integration of computational technologies with established gene therapy methodologies represents a routine application of known techniques to an existing medical treatment protocol, thereby rendering potential patent claims obvious under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,641
TitleMethod for the treatment of mucopolysaccharidosis type I
Assignee(s)Sangamo Therapeutics, Inc.